Latest News on BCAX

Financial News Based On Company


Advertisement
Advertisement

Stifel cuts Bicara Therapeutics stock price target on OpEx estimates

https://www.investing.com/news/analyst-ratings/stifel-cuts-bicara-therapeutics-stock-price-target-on-opex-estimates-93CH-5015076
Stifel has lowered its price target for Bicara Therapeutics Inc (NASDAQ:BCAX) to $43 from $45, while maintaining a Buy rating. This adjustment is attributed to increased operating expense estimates for fiscal year 2026 and beyond. Despite the company burning through cash, it holds more cash than debt and is progressing with its Phase 3 FORTIFI-HN01 trial, with an interim analysis expected in mid-fiscal year 2027.

Bicara Therapeutics Inc. Stock 12‑Month Price Target Cut to $31.82, Implies 219% Upside

https://www.tradingview.com/news/tradingview:7ea4d01682790:0-bicara-therapeutics-inc-stock-12-month-price-target-cut-to-31-82-implies-219-upside/
Bicara Therapeutics Inc. (BCAX) has seen its average 12-month price target reduced from $32.82 to $31.82 by 11 analysts, with individual forecasts ranging from $8 to $43 per share. This updated target suggests a potential upside of approximately 219% from its November 9 closing price. Despite the target cut, the consensus rating from 13 covering analysts remains a "Buy," with 12 Buy ratings and 1 Sell rating.

Bicara Therapeutics (BCAX) Reiterated at Market Outperform by Citizens - Pivotal Trial Advancing Rapidly

https://www.streetinsider.com/Analyst+Comments/Bicara+Therapeutics+%28BCAX%29+Reiterated+at+Market+Outperform+by+Citizens+-+Pivotal+Trial+Advancing+Rapidly/27317351.html
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and a $31.00 price target for Bicara Therapeutics (BCAX), citing strong third-quarter 2026 financial results and rapid advancement of its pivotal trial. The company expects initial mCRC data in January 2027 and holds a substantial cash position of $442.3 million, presenting an attractive investment opportunity.

What Bicara Therapeutics (BCAX) Said on Its Q3 Earnings Call

https://es.tradingview.com/news/marketbeat:a6a6985d1094b:0-what-bicara-therapeutics-bcax-said-on-its-q3-earnings-call/
Bicara Therapeutics (BCAX) announced that its pivotal study of FICERA for advanced head and neck cancer has sufficient enrollment for a top-line interim analysis in mid-2027, with plans for an interim overall survival analysis. The company aims for speed to market and a competitive regulatory submission, expecting to present further data for colorectal cancer in January 2027. Bicara ended Q3 2026 with $442.3 million in cash, projected to fund operations into the first half of 2029, despite increased R&D and G&A expenses.

What Bicara Therapeutics (BCAX) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:a6a6985d1094b:0-what-bicara-therapeutics-bcax-said-on-its-q3-earnings-call/
Bicara Therapeutics (BCAX) announced that its pivotal FORTIFI-HN01 study for FICERA in advanced HPV-negative head and neck cancer has sufficient enrollment for an interim analysis in mid-2027, with plans for an overall survival analysis. The company is preparing for potential market competition by focusing on a differentiated regulatory submission and clinical profile. Bicara also reported increased Q3 2026 R&D and G&A expenses, ending the quarter with $442.3 million in cash, expected to fund operations into the first half of 2029.
Advertisement

Bicara Therapeutics Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/63033031/bicara-therapeutics-q3-2026-earnings-call-transcript
Bicara Therapeutics reported increased R&D expenses and maintains a strong cash position expected to last into 2029. The company is advancing its pivotal FORTIFY HN01 study for Ficera in HPV-negative head and neck cancer, with an interim analysis expected mid-next year. Ficera, holding Breakthrough Therapy designation, shows promising early clinical results, and the company is strategically preparing for its potential U.S. launch in a growing market.

Earnings call transcript: Bicara Therapeutics Q3 2026 loss narrows focus on trial progress

https://ca.investing.com/news/stock-market-news/earnings-call-transcript-bicara-therapeutics-q3-2026-loss-narrows-focus-on-trial-progress-93CH-4943609
Bicara Therapeutics discussed its Q3 2026 financial results and provided updates on its lead cancer drug, FICERA, for HPV-negative head and neck cancer. The company reported increased R&D and G&A spending as it advances its pivotal FORTIFI-HN01 trial and prepares for potential commercialization. Management expects an interim overall survival analysis in mid-2027 and believes its cash reserves will fund operations into the first half of 2029.

Bicara Therapeutics Q3 2026 Earnings Call Is Live

https://www.tradingview.com/news/urn:live_audio:quartr.com:729042:0-bicara-therapeutics-q3-2026-earnings-call-is-live/
Bicara Therapeutics (BCAX) has commenced its Q3 2026 earnings call, where executives will discuss the latest financial results and answer questions from analysts. Investors following BCAX are encouraged to listen to management's commentary, which can significantly influence market sentiment. The call offers an opportunity to understand the details behind the reported numbers and potentially uncover surprise announcements.

Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

https://www.globenewswire.com/news-release/2026/11/09/3398297/0/en/bicara-therapeutics-reports-third-quarter-2026-financial-results-and-provides-business-update.html
Bicara Therapeutics Inc. announced its Q3 2026 financial results and business updates, highlighting substantial enrollment in the FORTIFI-HN01 pivotal trial for HPV-negative HNSCC, with topline results expected mid-2027. The company also detailed progress on its FORTIFI-FLEX alternate dosing study and upcoming presentations of preclinical and clinical data. Bicara reported a net loss of $71.2 million for the quarter, with cash reserves projected to fund operations into the first half of 2029.

BCAX: Bicara Therapeutics Inc. filed SEC Form 8-K: Results of...

https://www.quantisnow.com/insight/bicara-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6780286
Bicara Therapeutics Inc. reported its Q3 2026 results, with a net loss widening to $71.2 million, primarily due to increased research and development and administrative costs. The company announced substantial enrollment in its FORTIFI-HN01 pivotal trial for HPV-negative head and neck cancer, expecting interim results by mid-2027, and stated that its current cash reserves of $442.3 million are projected to fund operations into the first half of 2029.
Advertisement

BCAX: Bicara Therapeutics Inc. filed SEC Form 8-K: Results of...

https://quantisnow.com/insight/bicara-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6780286
Bicara Therapeutics Inc. reported its Q3 2026 results, showing a widened net loss of $71.2 million, up from $36.3 million in Q3 2025, primarily due to increased research and development expenses. Despite the loss, the company announced substantial enrollment in its FORTIFI-HN01 pivotal trial, with interim results expected mid-2027, and stated that its cash reserves of $442.3 million are projected to fund operations into the first half of 2029.

Bicara Therapeutics Inc. (BCAX) Seasonal returns chart

https://uk.finance.yahoo.com/quote/BCAX/seasonality/
This article from Yahoo Finance presents a seasonal returns chart for Bicara Therapeutics Inc. (BCAX), showing the average monthly price return from 2024 to 2026. It indicates that the company's stock, trading on NasdaqGM, closed at $8.65 with a 5.62% gain on November 6th. The article also notes an upcoming Q3 2026 earnings call for BCAX on November 9, 2026.

Bicara Therapeutics Inc. (BCAX) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/BCAX/
This article provides a comprehensive overview of Bicara Therapeutics Inc. (BCAX), a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. It details the company's stock performance, key financial metrics, analyst ratings, and an overview of its lead program, ficerafusp alfa. The stock closed at $8.89 on November 4, 2026, and an analyst from Goldman Sachs recently downgraded its rating to "Sell" with a lowered price target.

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/11/04/3395298/0/en/bicara-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Bicara Therapeutics Inc. announced an inducement grant to a new employee on November 2, 2026, under its 2026 Inducement Plan. The employee received a non-qualified stock option to purchase 50,000 shares of common stock at an exercise price of $7.93 per share, vesting over approximately four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment.

Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET

https://sg.finance.yahoo.com/news/bicara-therapeutics-report-third-quarter-133000403.html
Bicara Therapeutics Inc. announced it will report its third quarter 2026 financial results and provide business updates on November 9, 2026, before the market opens. The company will also host a conference call at 8:30 a.m. ET on the same day to discuss these updates. Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors.
Advertisement

Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET

https://www.manilatimes.net/2026/11/02/tmt-newswire/globenewswire/bicara-therapeutics-to-report-third-quarter-2026-financial-results-and-business-updates-on-november-9-2026-at-830-am-et/2459583/amp
Bicara Therapeutics Inc. announced that it will report its third quarter 2026 financial results and business updates before market open on Monday, November 9, 2026. The company will host a conference call to discuss these updates at 8:30 a.m. ET on the same day, with registration details and webcast access provided for interested participants. Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors.

Bicara Therapeutics to report Q3FY26 results on Nov 9

https://scanx.trade/stock-market-news/companies/bicara-therapeutics-report-q3fy26-results-nov-9/55174473
Bicara Therapeutics Inc. is scheduled to report its third-quarter 2026 financial results and business updates on Monday, November 9, 2026, before the market opens. The company will also host a conference call at 8:30 am ET on the same day to discuss these developments. Interested individuals can register via a provided link or access a live webcast on Bicara's website, with a replay available for 30 days.

Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET

https://www.manilatimes.net/2026/11/02/tmt-newswire/globenewswire/bicara-therapeutics-to-report-third-quarter-2026-financial-results-and-business-updates-on-november-9-2026-at-830-am-et/2459583
Bicara Therapeutics Inc. announced it will report its third quarter 2026 financial results and business updates on Monday, November 9, 2026, before market open. The company will host a conference call at 8:30 a.m. ET on the same day to discuss these updates. Interested individuals can register for the call or access a live webcast via the company's investor relations website.

Bicara Therapeutics to Report Third Quarter 2026 Financial

https://www.globenewswire.com/news-release/2026/11/02/3393152/0/en/bicara-therapeutics-to-report-third-quarter-2026-financial-results-and-business-updates-on-november-9-2026-at-8-30-am-et.html
Bicara Therapeutics Inc. (Nasdaq: BCAX) announced it will report its third-quarter 2026 financial results and business updates before the market opens on Monday, November 9, 2026. The company will host a conference call the same day at 8:30 a.m. ET to discuss these results. Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors.

Bicara Therapeutics (BCAX) Stock Forecast & Analyst Ratings

https://www.moomoo.com/stock/BCAX-US/forecast?chain_id=Name1K9-3FXPhg.1lcg597&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A59,%22f%22%3A%22www.moomoo.com%2Foptions%2FGLD261008C386000-US%22%7D
This article provides a stock forecast and analyst ratings for Bicara Therapeutics (BCAX). It includes details on analyst recommendations, price targets, and a brief overview of the company's recent performance. The content will help investors understand current market sentiment and potential future movements for BCAX.
Advertisement

Wedbush maintains Bicara Therapeutics at Outperform, lowers price target to $24 from $33

https://www.tradingview.com/news/tradingview:9abec71b092b2:0-wedbush-maintains-bicara-therapeutics-at-outperform-lowers-price-target-to-24-from-33/
Wedbush has reiterated its "Outperform" rating for Bicara Therapeutics (BCAX) but has reduced its price target from $33 to $24, a 27.3% decrease. Despite the reduction, the new price target still suggests a significant upside of 145.9% from the stock's closing price of $9.76 on October 28. Investors can find more detailed analyst data and ratings on TradingView's platform.

Goldman Sachs downgrades Bicara Therapeutics stock rating to sell

https://www.investing.com/news/analyst-ratings/goldman-sachs-downgrades-bicara-therapeutics-stock-rating-to-sell-93CH-4985332
Goldman Sachs has downgraded Bicara Therapeutics (NASDAQ:BCAX) to Sell from Neutral, setting an $8.00 price target, primarily due to narrowing competitive prospects for Bicara's ficera. This follows positive Phase 3 results for Genmab's petosemtamab, which showed superior efficacy in head and neck squamous cell carcinoma. Other analysts, including BofA Securities and Morgan Stanley, maintain more optimistic ratings for Bicara.

BofA reiterates Bicara Therapeutics stock rating on EGFR therapy potential

https://www.investing.com/news/analyst-ratings/bofa-reiterates-bicara-therapeutics-stock-rating-on-egfr-therapy-potential-93CH-4982282
BofA Securities reiterated a Buy rating and a $34.00 price target for Bicara Therapeutics (NASDAQ:BCAX) after the stock fell significantly following Genmab's positive phase 3 trial results for its EGFR therapy. Despite the market reaction, BofA views Bicara's ficerafusp alfa as having differentiated potential, especially in HPV-negative patients, and highlights the company's strong cash position and analyst revisions. Other firms like Morgan Stanley, Cantor Fitzgerald, Citizens, and BMO Capital also maintain positive ratings and price targets, underscoring confidence in Bicara's oncology pipeline.

BICARA THERAPEUTICS INC : WEDBUSH CUTS TARGET PRICE TO $24 FROM $33

https://www.moomoo.com/news/flash/1002756959/bicara-therapeutics-inc-wedbush-cuts-target-price-to-24-from
Wedbush has cut its target price for Bicara Therapeutics Inc. shares from $33 to $24. This revision reflects an updated outlook on the company's valuation by the analyst firm. Investors should note this change in analyst sentiment.

Bicara Therapeutics Inc. (BCAX) Stock Price | Live Quotes & Charts | NASDAQ

https://stockstotrade.com/quote/BCAX
Bicara Therapeutics Inc. (BCAX) stock is currently trading at $17.48, down significantly by 45.48%. The article provides live quotes and charts, but notes that there are no current analyst ratings or earnings information available for the company.
Advertisement

Bicara Therapeutics Falls 45% Today

https://stockstotrade.com/news/bicara-therapeutics-inc-bcax-news-2026-10-28/
Bicara Therapeutics Inc. (NASDAQ: BCAX) experienced a significant 45% drop in its stock price to $9.68, with no clear company news or filing to explain the sudden decline. The clinical-stage drug developer, focused on treatments for solid tumors, saw unusually active trading. Despite the sharp fall, the company's strong cash position is estimated to cover its operating expenses for approximately thirty-four months, providing a cushion for ongoing development.

Bicara Therapeutics stock hits 52-week low at 13.66 USD

https://www.investing.com/news/company-news/bicara-therapeutics-stock-hits-52week-low-at-1366-usd-93CH-4979645
Bicara Therapeutics Inc. (BCAX) stock recently reached a 52-week low of $13.66 but has since recovered slightly to $14, still well below its 52-week high of $30.99. Despite the weak price performance, 7 analysts have revised their earnings estimates upwards, and several firms have initiated or reiterated optimistic ratings, citing the potential of its drug candidates. This suggests improving sentiment and significant upside potential from current levels.

Bicara Therapeutics stock hits 52-week low at 13.66 USD By Investing.com

https://ng.investing.com/news/stock-market-news/bicara-therapeutics-stock-hits-52week-low-at-1366-usd-93CH-2763888
Bicara Therapeutics Inc. stock recently hit a 52-week low of $13.66, though it has since recovered slightly to $14. Despite the downturn, the stock has shown an 8.88% increase over the past year, and analysts remain optimistic, with upward revisions in earnings forecasts and price targets ranging from $20 to $45. Several analyst firms, including Morgan Stanley, Cantor Fitzgerald, Citizens, and BMO Capital, have initiated or reiterated positive ratings, citing the potential of Bicara's drug candidates like fimacimab and ficerafusp alfa in cancer treatment.

Bicara Therapeutics stock hits 52-week low at 13.66 USD

https://ca.investing.com/news/stock-market-news/bicara-therapeutics-stock-hits-52week-low-at-1366-usd-93CH-4909860
Bicara Therapeutics Inc. (BCAX) stock recently hit a 52-week low of $13.66, although it has since recovered slightly to $14. Despite the downturn, the stock shows an 8.88% one-year change, and 7 analysts have revised their earnings upwards for the upcoming period. Analysts maintain optimistic price targets ranging from $20 to $45, indicating significant upside potential, with several firms initiating or reiterating "Overweight" or "Outperform" ratings based on the potential of its drug candidates fimacimab and ficerafusp alfa.

Wedbush Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8479125/wedbush-keeps-their-buy-rating-on-bicara-therapeutics-inc-bcax/
Wedbush has maintained a Buy rating on Bicara Therapeutics Inc. (BCAX) with a price target of $33.00, aligning with a strong Buy consensus among analysts and an average target of $33.33. This positive outlook comes despite the company reporting an increased quarterly GAAP net loss of $55.44 million for the quarter ending June 30, compared to $27.39 million last year.
Advertisement

Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $45

https://www.moomoo.com/news/post/1002366778/stifel-maintains-bicara-therapeutics-bcaxus-with-buy-rating-maintains-target
Stifel has reiterated its Buy rating for Bicara Therapeutics (BCAX.US) and maintained a target price of $45. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Bicara Therapeutics Inc. (BCAX) latest press releases and corporate news

https://uk.finance.yahoo.com/quote/BCAX/press-releases/
This article provides an overview of recent press releases and corporate news for Bicara Therapeutics Inc. (BCAX). It highlights several announcements regarding inducement grants under Nasdaq Listing Rule 5635(c)(4), as well as the company's second-quarter 2026 progress report and strategic leadership transitions. The page also includes current stock performance data and a comparison to the S&P 500.

Bicara Therapeutics Inc. Estimates – NASDAQ:BCAX

https://www.tradingview.com/symbols/NASDAQ-BCAX/financials-estimates/
This page provides financial estimates for Bicara Therapeutics Inc. (NASDAQ: BCAX) on TradingView. Users can explore reported financial data and analyst estimates across various statements and metrics, comparing actual results with average, high, and low estimates, and visualizing trends over time. The available data covers income statements, balance sheets, and cash flow on both annual and quarterly bases.

Form 144 BICARA THERAPEUTICS INC. For: 21 October By Investing.com

https://za.investing.com/news/stock-market-news/form-144-bicara-therapeutics-inc-for-21-october-93CH-4518069
This article reports on a Form 144 filing by BICARA THERAPEUTICS INC., referencing activity on October 21st. The brief piece, published by Investing.com, notes the filing and includes the company's stock symbol BCAX, which was down 2.67%.

Form 144 BICARA THERAPEUTICS INC. For: 21 October By Investing.com

https://au.investing.com/news/stock-market-news/form-144-bicara-therapeutics-inc-for-21-october-93CH-4706168
This article reports on the filing of Form 144 for Bicara Therapeutics Inc., specifically for October 21. Form 144 is a notice of the intent to sell restricted securities. The article provides minimal additional detail beyond the filing's existence and the company involved.
Advertisement

Form 144 BICARA THERAPEUTICS INC. For: 21 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-bicara-therapeutics-inc-for-21-october-93CH-2749945
This article from Investing.com announces the filing of Form 144 for BICARA THERAPEUTICS INC. for October 21. Form 144 is a notice of the intent to sell restricted securities. The publication date is listed as October 22, 2026, at 01:46.

Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Raises Target Price to $41

https://www.moomoo.com/news/post/1001827124/morgan-stanley-maintains-bicara-therapeutics-bcaxus-with-buy-rating-raises
Morgan Stanley has reiterated its "Buy" rating for Bicara Therapeutics (BCAX.US) and increased its target price to $41. This indicates a positive outlook from the investment bank regarding the company's future performance and stock value.

Bicara Therapeutics (BCAX) Options Chain & Prices 2026

https://www.marketbeat.com/stocks/NASDAQ/BCAX/options/
This article provides an overview of Bicara Therapeutics (BCAX) options chain and prices for 2026, including specific call options expiring on November 20, 2026, with their respective strike prices, volumes, and implied volatilities. It details the company's current stock price and extended trading performance, along with various research tools and related company data for options trading.

BofA Securities Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $34

https://www.moomoo.com/news/post/1001697393/bofa-securities-maintains-bicara-therapeutics-bcaxus-with-buy-rating-maintains
BofA Securities has reiterated its Buy rating on Bicara Therapeutics (BCAX.US) and maintained its target price at $34. This continued endorsement suggests the firm's confidence in the company's future performance.

Morgan Stanley initiates Bicara Therapeutics stock with overweight rating By Investing.com

https://in.investing.com/news/stock-market-news/morgan-stanley-initiates-bicara-therapeutics-stock-with-overweight-rating-93CH-5641891
Morgan Stanley has initiated coverage of Bicara Therapeutics (NASDAQ: BCAX) with an overweight rating and a $41 price target, representing a 135% upside. The firm forecasts peak unadjusted global sales of $2.31 billion for Bicara's fimacimab candidate by 2036, primarily targeting HPV-negative head and neck squamous cell carcinoma. Bicara's strong financial position, with more cash than debt and a current ratio of 11.59, supports its path towards commercialization.
Advertisement

Morgan Stanley initiates Bicara Therapeutics stock with overweight rating

https://www.investing.com/news/analyst-ratings/morgan-stanley-initiates-bicara-therapeutics-stock-with-overweight-rating-93CH-4959074
Morgan Stanley has initiated coverage on Bicara Therapeutics Inc (NASDAQ: BCAX) with an overweight rating and a price target of $41, representing a 135% upside. The firm forecasts peak global sales of $2.31 billion for Bicara's fimacimab candidate in 2036, primarily targeting HPV-negative head and neck squamous cell carcinoma. Other analysts also hold positive ratings, and the company's strong financial position with more cash than debt supports its advancement toward commercialization.

BTIG reiterates Buy rating on Bicara Therapeutics, $39 price target

https://www.tradingview.com/news/tradingview:9bc8193e7582a:0-btig-reiterates-buy-rating-on-bicara-therapeutics-39-price-target/
BTIG reiterated its Buy rating on Bicara Therapeutics (BCAX) with a $39 price target, suggesting a 132.4% upside. The firm highlights the promising clinical efficacy of ficerafusp alfa in HPV-negative patients and projects substantial peak sales of $993 million for the drug in first-line recurrent/metastatic head and neck squamous cell carcinoma.

Bicara Therapeutics | SCHEDULE 13G/A: Others

https://www.moomoo.com/news/notice/307895920/bicara-therapeutics-schedule-13g-a-others
This article is a SCHEDULE 13G/A filing related to Bicara Therapeutics. A Schedule 13G/A is an amendment to a Schedule 13G, which is a short-form statement filed with the SEC by passive investors who own more than 5% of a company's stock. The "Others" designation likely refers to the type of filer or a specific category within the filing.

Press Release: Bicara Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.moomoo.com/news/post/1000605232/press-release-bicara-therapeutics-announces-inducement-grants-under-nasdaq-listing
Bicara Therapeutics announced inducement grants of stock options to two new employees. These grants, totaling 25,000 shares of common stock, were approved by the company's Compensation Committee and are intended to comply with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment. The options have a 10-year term and vest over four years.

T. Rowe Price lists 2.8 million shares in Bicara Therapeutics (BCAX) ownership amendment.

https://www.stocktitan.net/sec-filings/BCAX/schedule-13g-a-bicara-therapeutics-inc-amended-passive-investment-dis-f86a3bd3c9c6.html
T. Rowe Price Investment Management, Inc. has filed an ownership amendment for Bicara Therapeutics (BCAX), reporting beneficial ownership of 2,804,772 common shares, which constitutes 4.2% of the class, as of September 30, 2026. The filing indicates that T. Rowe Price holds sole voting power over 2,798,430 shares and sole dispositive power over all 2,804,772 shares. The firm explicitly states that the report should not be construed as an admission of beneficial ownership.
Advertisement

BMO Capital Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $35

https://www.moomoo.com/news/post/1000695948/bmo-capital-maintains-bicara-therapeutics-bcaxus-with-buy-rating-maintains
BMO Capital has reiterated its Buy rating for Bicara Therapeutics (BCAX.US) and maintained its price target at $35. This indicates continued confidence from the firm in the company's financial prospects and stock performance.

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

https://www.globenewswire.com/news-release/2026/10/05/3374533/0/en/bicara-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Bicara Therapeutics Inc. announced inducement grants on October 1, 2026, to two new employees. These grants consist of non-qualified stock options to purchase 207,150 shares of Bicara's common stock at an exercise price of $18.20 per share, vesting over time, and were approved under the company's 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors.

Bicara Therapeutics Inc. - Common Stock (Nasdaq:BCAX) Detailed Stock Data

https://markets.chroniclejournal.com/observerreporter/quote/detailedquote?Symbol=NQ%3ABCAX
This article provides detailed stock data for Bicara Therapeutics Inc. (Nasdaq: BCAX), including its current price, daily change, volume, and key financial metrics like EPS and price/earnings. It also presents price performance over various periods, such as year-to-date and 1-year changes, reflecting a significant increase in value.

Bicara Therapeutics' President Ryan Cohlhepp Reports Stock Option Exercise and Share Sales in Form 4 Filing

https://kalkinemedia.com/us/news/announcements/bicara-therapeutics-president-ryan-cohlhepp-reports-stock-option-exercise-and-share-sales-in-form-4-filing
Ryan Cohlhepp, President, COO, and Interim CEO of Bicara Therapeutics Inc., exercised stock options for 17,500 common shares and subsequently sold all of them in two tranches on September 8, 2026. These transactions were executed under a Rule 10b5-1 trading plan. Following the sales, Cohlhepp directly holds 181,641 shares and retains 34,252 stock options.

Cantor Fitzgerald reiterates Overweight on Bicara stock

https://m.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-overweight-on-bicara-stock-93CH-4896274?ampMode=1
Cantor Fitzgerald reiterated an Overweight rating on Bicara Therapeutics (NASDAQ: BCAX) stock, citing the undervaluation of the company given the potential of its drug ficerafusp in the HPV-negative head and neck squamous cell carcinoma market. The firm projects $1.5 billion in peak sales for ficerafusp and noted that growing anticipation of mid-2027 Phase 3 interim results could further boost share appreciation. Several other analyst firms, including Citizens, BMO Capital, Mizuho, BTIG, and Morgan Stanley, have also shown confidence in Bicara with positive ratings and increased price targets.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement